聆達股份(300125.SZ)擬1000萬元設立廈門子公司
格隆匯8月13日丨聆達股份(300125.SZ)公佈,為整合並統一管理公司現有對外投資業務,公司擬使用自有資金人民幣1000萬元在廈門投資設立全資子公司“正達(廈門)企業管理有限公司”(名稱暫定,以註冊登記部門核定為準;簡稱:標的公司)。
擬申請主要經營範圍:從事投資管理,企業管理諮詢服務,新能源科技、信息科技、通訊科技、智能科技領域內的技術開發、技術轉讓、技術諮詢、技術服務;從事貨物及技術的進出口業務;計算機軟件開發;計算機軟件及輔助設備、五金產品、通訊設備、機械設備及電子產品的銷售;自有設備租賃;廣告設計、製作、代理、發佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.